RFG Advisory’s Novo Nordisk NVO Stock Holding History

RFG Advisory’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.17M	Buy	66,135 +21,962	+50%	+$944K	0.05%	271
2026 Q1	$1.62M	Buy	44,173 +6,185	+16%	+$293K	0.03%	388
2025 Q4	$1.93M	Sell	37,988 -15,980	-30%	-$817K	0.04%	343
2025 Q3	$2.99M	Buy	53,968 +1,567	+3%	+$91.7K	0.06%	238
2025 Q2	$3.62M	Buy	52,401 +3,591	+7%	+$244K	0.09%	186
2025 Q1	$3.39M	Buy	48,810 +36,786	+306%	+$3.04M	0.09%	159
2024 Q4	$1.03M	Sell	12,024 -8,304	-41%	-$898K	0.03%	359
2024 Q3	$2.42M	Buy	20,328 +9,205	+83%	+$1.23M	0.07%	207
2024 Q2	$1.59M	Buy	11,123 +381	+4%	+$50.5K	0.05%	267
2024 Q1	$1.38M	Buy	10,742 +4,835	+82%	+$576K	0.05%	289
2023 Q4	$611K	Sell	5,907 -1,132	-16%	-$112K	0.02%	402
2023 Q3	$640K	Sell	7,039 -367	-5%	-$32.3K	0.03%	361
2023 Q2	$599K	Buy	7,406 +174	+2%	+$14.2K	0.03%	385
2023 Q1	$575K	Sell	7,232 -98	-1%	-$6.95K	0.03%	380
2022 Q4	$501K	Sell	7,330 -32	-0.4%	-$1.88K	0.03%	403
2022 Q3	$423K	Buy	7,362 +184	+3%	+$9.86K	0.02%	416
2022 Q2	$370K	Buy	7,178 +14	+0.2%	+$777	0.02%	414
2022 Q1	$398K	Buy	7,164 +124	+2%	+$6.36K	0.03%	365
2021 Q4	$394K	Sell	7,040 -30	-0.4%	-$1.63K	0.03%	346
2021 Q3	$339K	Buy	7,070 +22	+0.3%	+$1.06K	0.03%	328
2021 Q2	$295K	Sell	7,048 -120	-2%	-$4.65K	0.03%	358
2021 Q1	$242K	Buy	7,168 +184	+3%	+$6.55K	0.03%	383
2020 Q4	$245K	Sell	6,984 -400	-5%	-$13.8K	0.03%	381
2020 Q3	$256K	Sell	7,384 -108	-1%	-$3.6K	0.04%	349
2020 Q2	$245K	Buy	7,492 +90	+1%	+$2.87K	0.04%	329
2020 Q1	$223K	Sell	7,402 -22	-0.3%	-$655	0.04%	306
2019 Q4	$215K	Sell	7,424 -900	-11%	-$24.9K	0.04%	334
2019 Q3	$215K	Sell	8,324 -138	-2%	-$3.49K	0.04%	302
2019 Q2	$216K	Buy	+8,462	New	+$209K	0.05%	291

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

RFG Advisory's NVO Position: Q2 2026 in Review

RFG Advisory increased its Novo Nordisk (NVO) stake by 50% in Q2 2026, buying an estimated $944K and bringing the position to 66,135 shares worth $3.17M. The position accounts for 0.05% of the portfolio, ranked #271.

RFG Advisory first reported a position in NVO in Q2 2019 and has held it in 29 quarters since. The position peaked at $3.62M in Q2 2025. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

RFG Advisory held 66,135 shares of Novo Nordisk worth $3.17M as of Q2 2026.
RFG Advisory bought 21,962 Novo Nordisk shares in Q2 2026, an estimated $944K.
Novo Nordisk made up 0.05% of RFG Advisory's portfolio in Q2 2026, its #271 holding.
RFG Advisory first reported a position in Novo Nordisk in Q2 2019 and has held it in 29 quarters since.
RFG Advisory's Novo Nordisk position peaked at $3.62M in Q2 2025.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on RFG Advisory's 13F filing for Q2 2026, filed 15 Jul 2026.